Phosphoproteome reveals molecular mechanisms of aberrant rhythm in neurotransmitter‐mediated islet hormone secretion in diabetic mice

Yunqiang He, Qi Fu, Min Sun, Yu Q, Yucheng Liang, Jie Zhang, Rui Gao, Hemin Jiang, Hao Dai, Yuwei Liu, Xinyu Xu, Heng Chen, Kuanfeng Xu, Tao YangClinical 2022 · DOI

TL;DR

This study uses advanced proteomic and phosphoproteomic techniques to uncover how neurotransmitters like acetylcholine (ACh) and norepinephrine (NE) regulate insulin secretion in pancreatic islets. They found that in diabetic mice, this regulation is disrupted due to impaired innervation and altered protein phosphorylation, leading to abnormal insulin release, and importantly, that combined interventions targeting specific receptors and kinases can ameliorate these issues.

What Problem Does This Paper Address?

The precise molecular mechanisms by which neurotransmitters, specifically acetylcholine (ACh) and norepinephrine (NE), control the rhythmic secretion of hormones from pancreatic islets, particularly insulin, remain incompletely understood. While it's known that these neurotransmitters play a crucial role, how they fine-tune this secretion at a molecular level, especially in the context of diabetes where islet function is compromised, is a significant knowledge gap. Furthermore, the extent to which islet innervation is abnormal in diabetes and how this contributes to the disease's progression is an active area of research. This paper aims to bridge this gap by providing a detailed molecular picture of neurotransmitter-mediated islet hormone regulation and its dysregulation in diabetes.

Methods

The researchers employed a multi-faceted approach:

  • Immunofluorescence and Immunohistochemistry: Used to visualize the distribution of neurotransmitter markers (VACHT, TH, NET) and their receptors (muscarinic and adrenergic) within pancreatic islets and their localization in specific islet cell types (alpha, beta, delta).
  • Islet Perfusion and Cell Culture: Used to study the rapid effects of ACh and NE on hormone secretion in isolated islets and cell lines, respectively.
  • Quantitative Proteomics and Phosphoproteomics (Mass Spectrometry-based): This was a core technique. They analyzed the entire protein content (proteome) and the phosphorylated proteins (phosphoproteome) in islets treated with ACh or NE. This allowed them to identify changes in protein expression and, more importantly, post-translational modifications (phosphorylation) that are critical for signaling.
  • Bioinformatics Analysis: Sophisticated computational tools were used to analyze the vast proteomic and phosphoproteomic data. This included:
  • Principal Component Analysis (PCA): To identify overall patterns and differences between experimental groups.
  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Analysis: To understand the biological processes and signaling pathways affected by neurotransmitter stimulation.
  • Motif Analysis (iGPS and GSEA): To predict upstream kinases responsible for phosphorylating specific proteins and to identify kinase-substrate relationships.
  • Real-time RT-PCR: To quantify the mRNA expression levels of receptors and predicted kinases.
  • siRNA Interference: Used to specifically knock down the expression of key kinases in islet cell lines to assess their functional role in insulin secretion.
  • Western Blotting: To confirm protein expression and phosphorylation levels.
  • Diabetic Mouse Models: Various models of diabetes (high-fat diet, STZ-induced, NOD, ob/ob, db/db) were used to investigate the role of neurotransmitter signaling in different stages and types of diabetes.
  • Combined Interventions: Pharmacological interventions targeting specific receptors (M3 agonist, α2a agonist) and kinases were used to assess their ability to restore normal islet function.

Datasets

The study utilized data generated from their own experiments on mouse islets and pancreatic islet cell lines. The raw MS proteomics data has been deposited in the ProteomeXchange database under accession number PXD031491. No external datasets were explicitly mentioned for training or evaluation.

Key Insights and Ideas

  • Phosphorylation is Key, Not Just Expression: The study strongly suggests that the rapid regulation of islet hormone secretion by neurotransmitters relies more on altering protein phosphorylation (a post-translational modification) rather than changes in protein expression levels. This highlights the dynamic nature of cellular signaling.
  • Specific Kinases and Substrates Identified: The research pinpoints Ksr2 and Pkacb as key kinases involved in ACh and NE-mediated insulin secretion, respectively. Furthermore, they identified specific substrate proteins (e.g., Cadps for ACh, Mlxipl and Pdcd4 for NE) that are phosphorylated by these kinases.
  • Aberrant Innervation in Diabetes: Diabetic mice, particularly those with severe islet dysfunction, exhibit significantly decreased expression of neurotransmitter receptors, kinases, and their substrates. This points to a breakdown in the neural control of islet function in diabetes.
  • "Platform Phase" of Secretion: The study observed a distinct "platform phase" in islet hormone secretion modulated by ACh and NE, suggesting a pre-regulatory role for these neurotransmitters in preparing islets for energy intake.
  • Combined Intervention Potential: The most exciting finding is that a combination of targeting specific receptors (M3 for ACh, α2a for NE) and key kinases (Ksr2, Pkacb) can significantly improve insulin secretion and phosphorylation patterns in diabetic mice, offering a promising therapeutic avenue.

Key Results

  • Neurotransmitter Effects: ACh significantly increased insulin and somatostatin secretion, while NE primarily affected glucagon secretion and inhibited insulin/somatostatin.
  • Receptor Expression: Muscarinic receptor M3 and adrenergic receptor α2a were found to be the highest expressed subtypes.
  • Phosphoproteomic Changes: While protein expression showed minimal changes after neurotransmitter stimulation, phosphorylation levels were significantly altered, impacting pathways like synaptic signaling, calcium channel opening, and insulin signaling.
  • Diabetic Model Findings: In diabetic mice with poor islet function, the expression of key receptors, kinases, and substrates was significantly reduced.
  • Therapeutic Efficacy: Combined interventions with receptor agonists and kinase modulators improved insulin secretion and substrate phosphorylation in HFD and ob/ob mice, but not in severely diabetic db/db mice.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study acknowledges that islet isolation can disrupt the natural neural network and signaling within the whole organ. Future work will involve exploring regulatory effects in the whole pancreas using perfusion and addressing the challenge of neurotransmitter degradation.
  • Local vs. Global Understanding: The neural networks and cell-cell associations were primarily examined locally. Further research using advanced imaging techniques like confocal microscopy and 3D panoramic histology is suggested to gain a more comprehensive understanding of the neural network in the pancreas and islets.
  • Severity of Diabetes: The combined intervention strategy was effective in HFD and ob/ob mice but less so in severely diabetic db/db mice, suggesting that the degree of islet dysfunction influences treatment efficacy. This points to the need for early intervention.
  • Future Therapeutic Strategy: The authors propose that targeting neural signals in islets could be a promising strategy for pharmacological intervention in diabetes treatment, especially in the early stages.

Summary updated

Abstract

Abnormal innervation was closely associated with the degree of islet dysfunction in diabetic mice and the aberrant rhythm in insulin secretion could be ameliorated significantly after intervention with key receptors and kinases in the early stage of diabetes mellitus, which may provide a promising therapeutic strategy for diabetes mellitus in the future.
BibTeX
@inproceedings{he2022phosphoproteome,
  author = {Yunqiang He and Qi Fu and Min Sun and Yu Q and Yucheng Liang and Jie Zhang and Rui Gao and Hemin Jiang and Hao Dai and Yuwei Liu and Xinyu Xu and Heng Chen and Kuanfeng Xu and Tao Yang},
  title = {{Phosphoproteome reveals molecular mechanisms of aberrant rhythm in neurotransmitter‐mediated islet hormone secretion in diabetic mice}},
  booktitle = {Clinical},
  year = {2022},
  doi = {10.1002/ctm2.890},
}
Figure